PMID- 31489570
OWN - NLM
STAT- MEDLINE
DCOM- 20191223
LR  - 20191223
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Linking)
VI  - 39
IP  - 10
DP  - 2019 Oct
TI  - Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in 
      China.
PG  - 1009-1018
LID - 10.1007/s40261-019-00836-y [doi]
AB  - Mecapegfilgrastim (HHPG-19K) is a long-acting pegylated recombinant human 
      granulocyte-colony stimulating factor (rhG-CSF) that is administered 
      subcutaneously as prophylaxis once per chemotherapy cycle as a weight-adjusted 
      dose of 100 microg/kg or as a 6 mg fixed dose. It is approved in China to reduce the 
      incidence of infection, as manifested by febrile neutropenia, in patients with 
      non-myeloid malignancies receiving myelosuppressive anti-cancer therapy 
      associated with a clinically significant incidence of febrile neutropenia. In 
      phase III trials, once per cycle prophylaxis with mecapegfilgrastim was more 
      effective than placebo in reducing the incidence of grade >/= 3 neutropenia in 
      cycle 1 in patients with advanced non-small cell lung cancer and was more 
      effective than filgrastim at reducing the mean duration of grade >/= 3 neutropenia 
      in cycle 1 in patients with breast cancer. The tolerability and safety profiles 
      of mecapegfilgrastim were similar to those of filgrastim, with no unexpected 
      adverse events (AEs); most adverse reactions in cycle 1 were mild or moderate in 
      severity. Thus, mecapegfilgrastim is an effective and generally well tolerated 
      treatment option for patients with non-myeloid malignancies receiving 
      myelosuppressive chemotherapy, and extends the options available for managing 
      chemotherapy-induced neutropenia in China.
FAU - Al-Salama, Zaina T
AU  - Al-Salama ZT
AD  - Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. 
      demail@springer.com.
FAU - Keam, Susan J
AU  - Keam SJ
AD  - Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Recombinant Proteins)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - I4QL0KKG3K (pegylated granulocyte colony-stimulating factor)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Breast Neoplasms/drug therapy/epidemiology
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/epidemiology
MH  - China/epidemiology
MH  - Female
MH  - Granulocyte Colony-Stimulating Factor/*therapeutic use
MH  - Humans
MH  - Lung Neoplasms/drug therapy/epidemiology
MH  - Male
MH  - Neutropenia/*chemically induced/epidemiology/*prevention & control
MH  - Polyethylene Glycols/*therapeutic use
MH  - Recombinant Proteins/therapeutic use
EDAT- 2019/09/07 06:00
MHDA- 2019/12/24 06:00
CRDT- 2019/09/07 06:00
PHST- 2019/09/07 06:00 [pubmed]
PHST- 2019/12/24 06:00 [medline]
PHST- 2019/09/07 06:00 [entrez]
AID - 10.1007/s40261-019-00836-y [pii]
AID - 10.1007/s40261-019-00836-y [doi]
PST - ppublish
SO  - Clin Drug Investig. 2019 Oct;39(10):1009-1018. doi: 10.1007/s40261-019-00836-y.